Hypercalcaemia in patients with breast cancer: Patterns and treatment outcomes among in-patients in a Malaysian tertiary healthcare facility by Bassam, Hassan & Zoriah, Aziz
Bassam & Zoriah 
Trop J Pharm Res, May 2017; 16(5): 1181  
 
Tropical Journal of Pharmaceutical Research May 2017; 16 (5): 1181-1186 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i5.28 
Original Research Article 
 
 
Hypercalcaemia in patients with breast cancer: Patterns 
and treatment outcomes among in-patients in a Malaysian 
tertiary healthcare facility 
 
Hassan Bassam* and Aziz Zoriah 
Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia 
 
*For correspondence: Email: bassamsunny@yahoo.com; Tel: +60164230950 
 
Sent for review: 19 August 2016        Revised accepted: 7 April 2017 
 
Abstract 
Purpose: To assess the patterns of use of bisphosphonate therapies for hypercalcaemia in breast 
cancer patients, and their outcomes.  
Methods: A retrospective chart review study of breast cancer patients hospitalised between 2009 and 
2014 at Penang Hospital, a public tertiary hospital in Malaysia was conducted. Patients with mild (total 
serum calcium = 10.5 - 11.9 mg/dl); moderate (12 - 12.9 mg/dl), and severe (≥13 mg/dl) hypercalcaemia 
at cancer diagnosis or during cancer treatment were included. Relevant data were extracted from 
medical records analyzed statistically.  
Results: From the records, 1,023 breast cancer patients were identified, 164 of which had 
hypercalcaemia at cancer diagnosis or during cancer treatment. About 25 % of the hypercalcaemic 
patients had advanced-stage cancer, while 20 % had severe hypercalcaemia. Regarding the pattern of 
bisphosphonate use, the results showed that more than half of the patients received pamidronate as 
first-line treatment; about a quarter were treated with zoledronic acid, while others received only normal 
saline. These treatments produced significant reductions in serum calcium levels relative to baseline 
values.  
Conclusion: Although zoledronic acid is considered as the treatment of choice for hypercalcemia of 
malignancy, the current study found that the first line treatment used for hypercalcemia is pamidronate, 
mainly because its cost is lower than that of zoledronic acid.  
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Hypercalcaemia is associated more with breast 
cancer than other cancers [1,2]. It is a life-
threatening condition characterised by serum 
calcium levels greater than 10.5 mg/dL, and 
serum albumin concentrations lower than 4 g/dL 
[1,2].  
 
Hypercalcaemia can occur in cancer patients 
with or without bone metastasis. The main 
mechanism of hypercalcaemia in these patients 
involves pathological bone resorption through 
secretion of cytokines such as parathyroid 
hormone-related protein (PTHrP), which leads to 
activation and differentiation of osteoclast cells 
[3-5]. 
  
In the last decade, many studies looked at the 
main risk factors for hypercalcaemia. Some of 
these risks, such as cancer stage, tumour size, 
and metastasis, were associated with incidence 
and/or severity of hypercalcaemia, but few 
studies have focused on the effectiveness of 
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different hypercalcaemia treatments, which 
remains controversial [5-8]. Thus there is need 
for more studies to assess the pattern of use, 
effectiveness of different treatments, with a view 
to guiding clinical management of 
hypercalcaemia, and reducing mortalities 
associated with the disease [9]. Iwase and 
colleagues have since 2001, highlighted this 
dearth of information on hypercalcaemia 
treatment, particularly at different stages of solid 
cancer [10].  
 
Bisphosphonates (such as alendronate, 
ibandronate, pamidronate, and zoledronic acid) 
are osteoclast inhibitors. They are currently used 
in oncology particularly for patients with 
hypercalcaemia due to bone metastatic breast 
cancer. Several studies conducted in various 
parts of the world have demonstrated the 
beneficial effects of bisphosphonates in 
hypercalcaemic patients [11,12]. While clinical 
trials support the use of bisphosphonates in 
breast cancer patients with hypercalcaemia, 
documentation of their day-to-day use i.e., 
pattern of use in clinical practice in Malaysia is 
still limited. Moreover, various studies indicate 
that further studies are needed to clarify 
effectiveness, pattern of use, how best to monitor 
treatment, and how to use bisphosphonates in a 
cost-effective manner among breast cancer 
patients [11,12]. Therefore, the aim of the 
present study was to review the pattern of use of 
bisphosonate therapies for hypercalcaemia in 





Study design and setting 
 
Authors conducted a retrospective chart review 
between 2009 and 2014 at Penang Hospital, 
located in the State of Penang Island, Malaysia. 
Penang Hospital is the largest public hospital in 
North Malaysia, and a referral centre for cancer 
patients. 
 
Ethical approval  
 
This study was approved by the National 
Medical Research Register, Research and 
Technical Support, Level 12, Ministry of 
Health Malaysia (no. NMRR-10-59-5057), 
and international guidelines for human 
studies were followed [13].  
 
Patients and data 
 
Patients admitted to Penang Hospital between 
2009 and 2014 were eligible for inclusion in this 
study if they were aged 18 years or above, and 
had a diagnosis of primary or advanced breast 
cancer. Early stages or primary stages of breast 
cancer include stages I, II, and III; while stage IV 
is the advanced stage [14,15]. To ensure a new 
diagnosis, patients were excluded if before the 
reference episode they had had any diagnosis of 
hypercalcemia or had used any 
antihypercalcemia drug. Moreover, patients were 
only included in this analysis if they had a 
calcium level measurement at baseline before 
starting anti-hypercalcemia treatment and at the 
reference time point. Also they were included if 
they had diagnosis of hypercalcaemia (serum 
calcium level above 10.5 mg/dL or greater than 
2.5 mmol/L) at cancer diagnosis or during cancer 
treatment; and had a normal or almost normal 
levels of alanine aminotransferase ALT), 
aspartate aminotransferase (AST), and serum 
total bilirubin.  
 
Patients were considered ineligible if they had 
used thiazides or furosemide diuretics or 
calcitonin 7 days prior to the study; or had a 
diagnosis of hyperparathyroidism, 
hyperthyroidism, adrenal insufficiency, renal 
impairment or failure; or had haematological 
malignancy such as multiple myeloma, non-
Hodgkin lymphoma or Hodgkin lymphoma; or 
had thyroid or kidney cancer [16-18].  
 
Hypercalcaemia treatment data 
 
Information about treatment was obtained from 
medical records and software data which showed 
the time and all the required data related with the 
treatment type, dose, time and duration. Patients 
were classified on the basis of treatment 
received i.e. normal saline, pamidronate (90 mg 
via 2 h infusion) or zoledronic acid (4 mg via 15 
minutes infusion). 
 
Classification of hypercalcaemia 
 
Serum calcium levels were collected before and 
after start using anti-hypercalcemia treatment 
i.e., base line. When serum calcium level 
between 10-5-11.9mg/ dL it will be considered as 
mild hypercalcemia. While, when it is between 
12-12.9 mg/ dL it will be considered as moderate 
hypercalcemia, and severe hypercalcemia will be 




Data analysis was performed using Statistical 
Package of Social Science (SPSS®) version 20. 
Descriptive statistics were used for demographic 
and clinical characteristics of the patients 
included. A one-way repeated measures ANOVA 
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was conducted to compare means of calcium 
levels before start using anti-hypercalcemia 
treatment (i.e., at baseline) and after 
hypercalcaemia treatments at three different 
times: Time 1 (with first dose; started after 
hypercalcemia diagnosis immediately), Time 2 
(with second dose; started after 3 - 4 weeks from 
the first dose), and at Time 3 (with third dose; 
started after 3 - 4 weeks after the second dose) 






A total of 1,023 patients diagnosed with breast 
cancer were treated in Penang Hospital during 
the study period. Among these, 164 were 
diagnosed with hypercalcaemia at cancer 
diagnosis or during cancer treatment, and were 
therefore included in current study. Table 1 
shows the characteristics of the patients. About 
half of the patients were Malay 81 (49.4 %), and 
about 73 (45 %) had stage III cancer. Majority of 
them 127 (77.4 %) did not have metastasis. More 
than half 93 (56.7 %) were placed on 
pamidronate, while about a quarter 42 (25.6%) 
received zoledronic acid. The mean age (years) 
of the patients was 54.1 years (SD = 11.2). The 
youngest patient was 22 years old while the 
oldest was 73 years old. More than half 93 (56.7 
%) of the 164 patients with hypercalcaemia had 
moderate hypercalcaemia, while only 25 (15.3 
%) had severe hypercalcaemia (Table 1). 
 
Pattern of use and treatment effect on serum 
calcium levels 
 
As it is obvious majority of the hypercalcemic 
patients were treated with pamidronate 93 (56.7 
%) i.e., first line treatment, followed by zoledronic 
acid 42 (25.6 %), and finally came normal saline 
29 (17.7 %).  
 
The initial calcium level and choice of initial 
treatment were related in some instances, for 
example pamidronate was more likely to be 
given to patients with moderate hypecalcemia. 
Zoledronic acid was mainly given for those who 
suffered from severe hypercalcemia. While, 
normal saline mainly was given to those with mild 
hypercalcemia. For patients given just normal 
saline, there was a significant effect for time, 
Wilks’ Lambda = 0.19, F (3, 26) = 36.82, p < 
.0001, multivariate partial eta squared = 0.81. 
Similarly, for patients treated with pamidronate, 
there was a single effect for time. Wilks’ Lambda 
= 0.07, F (3, 90) = 411.23, p < .0001, multivariate 
partial eta squared = 0.93. Likewise, for patients 
treated with zoledronic acid there was also 
significant effect of time, Wilks’ Lambda = 0.05, F 
(3, 39) = 251.04, p < .0001, multivariate partial 
eta squared = 0.95. 
 
Hypercalcaemia in the breast cancer patients 
was significantly reduced by each treatment 
(Table 2). Even the three treatments used i.e., 
pamidronate, zoledronic acid, and normal saline 
showed significant reduction in calcium level. But 
zoledronic acid is the most effective and superior 
compare with the pamidronate and normal saline 




While clinical trials support the use of 
bisphosphonates in breast cancer patients with 
hypercalcaemia [17], data on their use in clinical 
practice is limited. Based on literature review, the 
present study is the first to show that the pattern 
of   anti-hypercalcemia   treatment   use    among  
 
 
Table 1: Characteristics of the breast cancer patients studied (n=164) 
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8 (4.8) 
     
Values in parentheses are percentages 
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Table 2: Calcium levels at baseline, first dose, second dose, and third dose for patients treated with normal 




                        Number and Mean calcium levels of patients (mg/dL) 
Baseline Time 1  
(First dose)             
Time 2  
(Second dose)                 
Time 3 
(Third dose) 
Pamidronate 93 12.6 (0.7) 12.1 (0.6)         11.5 (0.6)   
Zoledronic acid 42 13.0 (0.7)          12.6 (0.7)        11.9 (0.5) 
Normal saline 29 11.2 (0.3)          10.9 (0.3)        10.6 (0.3) 
     Values are mean ± SD (p ≤ 0.05) 
 
breast cancer patients in Malaysia. Findings 
showed that more than half of the 
hypercalcaemic breast cancer patients mainly  
those who suffered from moderate 
hypercalcemia and few of those who suffered 
from severe one were treated with pamidronate 
(as a first-line treatment) than with zoledronic 
acid, although the two drugs significantly reduced 
calcium levels from baseline values. It is worth 
noting that patients with severe hypercalcaemia 
either received pamidronate or zoledronic acid. 
Normal saline alone is frequently used as an 
initial treatment for overcoming dehydration and 
to compensate for fluid loss due to polyuria. The 
use of normal saline is optional, and is most 
common for patients with asymptomatic mild 
hypercalcaemia under observation prior to 
commencement of their anti-neoplastic 
treatments. Normal saline is also optional for 
patients who already show clinical signs and 
symptoms of hypercalcaemia [18,19]. 
 
The apparent preference for pamidronate 
observed in this study, could probably be due to 
its lower cost. Indeed the generic version of 
pamidronate is 10 times less expensive than 
zoledronic acid [20]. In a retrospective study 
conducted by Spizzo and his colleagues in which 
routine uses of pamidronate and zoledronic acid 
were compared in patients with non-small cell 
lung cancer (NSCLC), it was reported that 
pamidronate was a well-tolerated and cost-
effective alternative to zoledronic acid [21]. 
These researchers also recommended that 
randomised studies be carried out to compare 
various bisphosphonate treatments with a view to 
determining the best treatment for NSCLC 
patients with bone metastasis. Other studies 
showed that the frequency and potency of 
pamidronate use are parallel to, or exceed those 
of zoledronic acid, especially among multiple 
myeloma or metastatic breast cancer patients 
[22]. On the other hand, results from some 
studies suggest that zoledronic acid is more 
frequently used than pamidronate because it is 
more potent and is associated with fewer side 
effects. Sanfilippo et al compared the 
effectiveness of zoledronic acid and pamidronate 
on survival of patients with multiply myeloma 
[23]. They found that zoledronic acid was 
superior to pamidronate, since patients receiving 
zoledronic acid had 22 % mortality reduction, 
compared to those on pamidronate [35]. Other 
studies showed that two low doses of zoledronic 
acid (4 mg and 8 mg) are superior to a single, 
higher dose of pamidronate (90 mg) in treating 
patients suffering from moderate and severe 
hypercalcaemia [12,20,24]. 
 
However, present study (i.e. non-randomised) 
was not designed to compare efficacies of 
pamidronate and zoledronic acid or treatment 
regimens, but only to review patterns of their 
clinical uses for treating hypercalcaemia and 
their overall effects on serum calcium levels. 
Very few patients in present study had bone 
scan. It was performed only when breast cancer 
was at advanced stage or when patients 
complained of pain in the bones. Indeed, de la 
Cueva et al [25] have advised that bone scan is 
not necessary in the early stages of breast 
cancer, but is mandatory for patients with stage 
IIB cancer, and tumour size equal to or more 
than 2 cm. However, a bone scan is useful for 
identifying the aetiology of hypercalcaemia 
because it may be either due to bone metastases 
or PTHrP produced by cancer tissues [25]. 
 
Limitations of the study 
 
There are several limitations to the present 
study. First the sample demography reflects 
Penang population, and therefore may not be 
generalized to hospitals or populations in other 
areas. Secondly, our inclusion criteria required 
that the patient received only bisphosphonates, 
and excluded patients treated with 
bisphosphonates and furosemide, thus reducing 
the number of breast cancer patients with 
hypercalcaemia in the study. Moreover, this 
study is a retrospective chart review; the primary 
data source is clinical records. Since clinical 
records are not designed for research, the 
findings may be limited by the degree of 
accuracy and completeness of the clinical 
records.   
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The findings of the present study show that 
pamidronate is the most widely prescribed anti-
hypercalcemic treatment (i.e., first-line treatment) 
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